The need for genetics/genomics literacy in cardiovascular/stroke care

Donna K. Arnett, PhD, MSPH
President
American Heart Association/
American Stroke Association

Financial Disclosure: None
Unlabeled/Unapproved Uses Disclosure: None
Tremendous progress in understanding of the genetic basis of cardiovascular and stroke disorders via GWAS studies

GWAS studies selectively assay a subset of nucleotides (“single-nucleotide polymorphisms,” SNPs) on all chromosomes in the genome. These polymorphisms are relatively common in populations.
GWAS of 200,000 Individuals of European Descent

Genetic Variants Associated with SBP

Loci reaching genome-wide significance are labeled in red

Intern Consortium BP GWAS: Nature 2011;478:103-109
Manhattan plots for All Ischemic Stroke
–log10(p) by genomic position
Manhattan plots for Large-Vessel Disease and Cardioembolic Stroke
\(-\log_{10}(p)\) by genomic position

- HDAC9
- PITX2
- 9p21
- ZFHX3
Whole exome/ genome sequencing studies selectively assay the protein coding regions ("exons") on all chromosomes in the genome.

Sequence data finds polymorphisms that are common and rare in populations.
State-of-the-science

• Exome sequencing has discovered new genes involved in cholesterol metabolism and blood pressure control

• Functional characterization of novel cardiovascular/stroke loci and genes is underway – among the most advanced of any discipline
From genotype to phenotype

ARTICLES

Biological, clinical and population relevance of 95 loci for blood lipids

A list of authors and their affiliations appears at the end of the paper.

Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides are among the most important risk factors for coronary artery disease (CAD) and are targets for therapeutic intervention. We report the association of 95 loci with plasma lipids in 10,000 individuals from four population-based studies (4,000 individuals in each of four studies).

ARTICLES

From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus

Kiran Musunuru\textsuperscript{1,2,3,*}, Alanna Strong\textsuperscript{4,*}, Maria Frank-Kamenetsky\textsuperscript{5}, Noemi E. Lee\textsuperscript{1}, Tim Ahfeldt\textsuperscript{1,6}, Katherine V. Sachs\textsuperscript{4}, Xiaoyu Li\textsuperscript{9}, Hui Li\textsuperscript{4}, Nicolas Kuperwasser\textsuperscript{1}, Vera M. Ruda\textsuperscript{1}, James P. Pirruccello\textsuperscript{1,2}, Brian Muchmore\textsuperscript{2}, Ludmila Prokunina-Olsson\textsuperscript{7}, Jennifer L. Hall\textsuperscript{2,8}, Eric E. Schadt\textsuperscript{9}, Carlos R. Morales\textsuperscript{10}
Clinical applications

• Despite the wealth of new knowledge…

• …cardiovascular and stroke clinical care has not yet been significantly impacted

• Translation into the clinic will ensue and accelerate over the next 5-10 years
Cardiovascular risk prediction

• Common DNA variants

• Rare DNA variants
In most cases, have been discovered by GWAS

Typically have small effects – no one variant will singlehandedly determine if a patient will develop disease

Can aggregate the effects of many variants by combining them into genetic risk scores
Genetic risk scores

• Genetic risk scores have been tested for predictive power for several cardiovascular/stroke disorders

• Modest predictive power for incident coronary heart disease – high genetic risk score confers only a ~70% increase in risk

• Limited clinical usefulness (except perhaps for intermediate-risk, “on the fence” patients)
Rare DNA variants

- Rare DNA variants have potential to have large effects, may increase (or decrease) risk several-fold

- However, each variant only found in one or a few people

- Genetic risk scores with common DNA variants do not capture – and may be trumped by – rare variants
Needle in a haystack

• Whole-genome sequencing will identify hundreds of rare variants in each person – most of which are irrelevant to disease

• How to know which rare variants are clinically important? Huge challenge for the field

• May fall in genes already implicated in disease, e.g., hypertrophic cardiomyopathy (HCM)
What does it mean to have a mutation?

• Even if in known gene, two problems

• First: the particular mutation may or may not affect gene function – difficult to predict *a priori*

• Second: even if the mutation changes gene function, penetrance may be affected by genetic background

• Even within a family, some members with HCM mutation will develop disease, some will not
Dangers of genetic information

• DTC testing (e.g., 23andMe) informs patients of genetic risk scores but (for now) not rare variants – possibility of false reassurance (or false worry)

• Problem will get worse with DTC genome sequencing

• Providers need to be aware of the limitations of this information to appropriately counsel patients

• Providers’ lack of knowledge about genetics will serve patients poorly – education is critical
Pharmacogenomics

• Getting the right dose of the right medication to the right patient

• Though integrated into clinical practice in some disciplines (e.g., oncology), not yet adopted in cardiovascular/stroke care

• Several emerging applications: warfarin, clopidogrel, beta-blockers, lipid-modifying medications
Clopidogrel and *CYP2C19*

- Patients presenting with myocardial infarction

- Routine practice is to give anti-platelet agent clopidogrel (Plavix), a type of thienopyridine

- Clopidogrel reduces risk of future cardiovascular event as well as the risk of in-stent thrombosis
**Clopidogrel and CYP2C19**

- *CYP2C19* encodes a key enzyme in making active metabolite of clopidogrel

- Reduced-function *CYP2C19* alleles result in decreased clopidogrel efficacy (but not other thienopyridines) – has lead to FDA black box warning
Effect of CYP2C19 reduced-function alleles

carriers

non-carriers

cardiovascular events

Patient presents to hospital with myocardial infarction

Determine patient’s CYP2C19 genotype

Normal alleles: give clopidogrel, cath lab, etc.

Reduced-function alleles: give a different thienopyridine (e.g., ticagrelor) or 2X dose of clopidogrel, cath lab, etc.

Pharmacogenomic strategy using CYP2C19
Clopidogrel and CYP2C19

• Point-of-care CYP2C19 genotyping presently being piloted by a number of hospitals

• Remains to be validated by clinical studies – unclear which patients, if any, would benefit

• Must be validated before can be recommended for routine clinical use
Adoption of pharmacogenomics

• With several cardiovascular pharmacogenomic applications under evaluation, likely that at least one will be validated within 5 years

• Expect rapid adoption by academic centers and large healthcare networks

• Expect slower adoption by individual practitioners, small group practices due to “knowledge gap” – education is critical
Provider education

• Although lack of provider education on genetics/genomics issues not currently jeopardizing clinical care – anticipate that negative effects of a “knowledge gap” will emerge in 5-10 years

• AHA/ASA is moving to address the anticipated need for provider genetics/genomics literacy in two ways
Scientific Statements

• To date, AHA/ASA has published several scientific statements related to genetics – e.g., “Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease” – but these are oriented to state-of-the-science and policy, not provider education

• Currently has a working group formulating a statement on “Use of Genetics and Genomics in Cardiovascular and Stroke Patient Care” – exclusively focused on provider education
Outline of Statement

• Primer on genetics and genomics
• Monogenic cardiovascular and stroke disorders
• Polygenic cardiovascular and stroke disorders
• Cardiovascular and stroke risk prediction
• Pharmacogenomics
• Cardiovascular and stroke risk prediction
• Social and ethical implications
• Educational resources
Massively open online course (MOOC)

- AHA/ASA monitoring latest trends in education

- Formulating an online course in Genetics/Genomics that will cover all of the topics outlined in the “Use of Genetics and Genomics in Cardiovascular and Stroke Patient Care” statement

- Plan to make course freely available to the biomedical community – pitched at an undergraduate level, with target audience of physicians, RNs, pharmacists, etc.
Massively open online course (MOOC)

• Will eventually be supplemented with modules on specific cardiovascular genetic disorders – e.g., hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, long QT syndrome, Brugada syndrome

• Initial versions in English, to potentially be followed by translations into other languages
Special Thanks To:

Dr. Kiran Musunuru MD PhD MPH
Assistant Professor
Harvard University